Emergent BioSolutions | EBS - Capitale Di Prestito





Capitale Di Prestito Cambiamento Data
Acadia Pharmaceuticals USD 0 0 2025-03
Akebia Therapeutics USD 48.25M 609K 2025-12
ALKERMES USD 285.82M 639K 2024-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
ANI Pharmaceuticals USD 291.84M 5.84M 2025-12
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Coherus Biosciences USD 51.08M 496K 2025-12
Emergent BioSolutions USD 446.5M 1.7M 2023-12
Glaxosmithkline GBP 19.82B 203.13M 2025-12
Heron Therapeutics USD 140.64M 975K 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
Lexicon Pharmaceuticals USD 49.41M 7.1M 2025-12
Lonza CHF 3.88B 323M 2025-12
Merck USD 39.97B 6B 2025-09
Moderna USD 610M 584M 2025-12
Myriad Genetics USD 119.9M 400K 2025-12
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Pacira USD 372.19M 4.53M 2025-12
Pfizer USD 57.41B 93M 2025-09
PTC Therapeutics USD 2.03B 193.22M 2025-12
Sanofi EUR 15.72B 2.45B 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
United Therapeutics USD 100M 100M 2024-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12
Xoma USD 94.38M 7.82M 2025-09